CL
BTAI icon

CSS LLC’s BioXcel Therapeutics BTAI Stock Holding History

CSS LLC’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-300
Closed -$57K – 963
2022
Q3 		$57K Sell
300
-625
-68% -$145K ﹤0.01% 871
2022
Q2 		$195K Buy
+925
New +$195K 0.01% 807
2022
Q1 		– Sell
-344
Closed -$112K – 1178
2021
Q4 		$112K Buy
+344
New +$148K ﹤0.01% 995
2021
Q3 		– Sell
-100
Closed -$46K – 1187
2021
Q2 		$46K Sell
100
-219
-69% -$119K ﹤0.01% 1000
2021
Q1 		$220K Sell
319
-2,450
-88% -$1.97M 0.01% 748
2020
Q4 		$2.05M Buy
2,769
+144
+5% +$112K 0.08% 191
2020
Q3 		$1.82M Buy
2,625
+2,494
+1,904% +$1.87M 0.09% 193
2020
Q2 		$111K Buy
+131
New +$85.4K 0.01% 542

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

CSS LLC's BTAI Position: Q4 2022 in Review

CSS LLC sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 1,122 shares — an estimated $212K sold.

CSS LLC first reported a position in BTAI in Q2 2020 and held it in 10 quarters. The position peaked at $1.58M in Q1 2021. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

  • CSS LLC reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 1,122 BioXcel Therapeutics shares in Q4 2022, an estimated $212K.
  • CSS LLC first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 10 quarters.
  • CSS LLC's BioXcel Therapeutics position peaked at $1.58M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.